Vanderbilt Ingram Cancer Center

Park named to new role as deputy director of Vanderbilt-Ingram Cancer Center

Ben Ho Park, MD, PhD, Cornelius Abernathy Professor of Medicine, has been named deputy director of Vanderbilt-Ingram Cancer Center (VICC).

Rocker George Thorogood, right, shown here with Ronald Alvarez, MD, MBA, recently made a donation to Vanderbilt-Ingram Cancer Center (VICC) from the Marla Thorogood Memorial Fund for Ovarian Cancer Research and plans to do more in memory of his wife, Marla, who he lost to ovarian cancer in 2019. In September, a limited-edition T-shirt featuring the Destroyers logo will be available for purchase online and at shows during the “Good to Be Bad Tour.” Sales will benefit cancer research at VICC.

Supporting ovarian cancer research

Rocker George Thorogood recently made a donation to Vanderbilt-Ingram Cancer Center (VICC) from the Marla Thorogood Memorial Fund for Ovarian Cancer Research.

Jackson elected fellow of American Association of Nurse Practitioners

Heather Jackson, PhD, APRN, administrative director of Advanced Practice for Vanderbilt-Ingram Cancer Center, has been elected a fellow of the American Association of Nurse Practitioners.

Clinical trial to test immunotherapy for rectal cancer

A new clinical trial seeks to determine whether immunotherapy in combination with short-course radiation followed by surgical resection could be a curative treatment for locally advanced rectal cancer.

Davis promoted to Vice President for VUMC Cancer Care Network and Strategy

Nancy Davis, MD, has been promoted to Vice President for Cancer Care Network and Strategy at Vanderbilt University Medical Center, a new position responsible for developing provider relationships with other health care systems and expanding access to oncology care throughout Tennessee and other states.

Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma

A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.

1 9 10 11 12 13 55